Keywords
Dietary protein
Glp -1 receptor agonists
Nutritional requirement
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the nutritional strategies described in the literature for anti-obesity therapy with glucagon-like peptide-1 receptor agonists. Methods: This is an integrative review whose guiding question is: "What nutritional strategies are reported in anti-obesity treatment with glucagon-like peptide-1 receptor agonists?" The review was structured in the stages of question formulation, sampling, categorization, evaluation, interpretation, and synthesis. The search was conducted in November 2025 in the MEDLINE/PubMed, Scopus, and Web of Science databases, using Health Science Descriptors and Medical Subject Headings combined by the Boolean operator, AND. Results: Ten studies were included, predominantly observational designs. The main strategies identified involved: assessment and monitoring of energy/protein and micronutrient intake (vitamin D, iron, B12), guidance on protein distribution throughout the day, management of gastrointestinal symptoms to prevent decreased intake, encouragement of hydration, monitoring of body composition, and association with resistance exercise to preserve lean mass. Final considerations: Anti-obesity therapy with glucagon-like peptide-1 receptor agonists should be accompanied by systematized nutritional interventions, focusing on protein adequacy, prevention of deficiencies, and symptom management.
References
BRASIL. Ministério da Saúde. Vigitel Brasil 2023: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília, DF: Ministério da Saúde, 2024. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2023.pdf. Acesso em: 2 nov. 2025.
BUTSCH WS, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using glucagon-like peptide-1 receptor agonists: a retrospective observational study. Obesity Pillars, 2025; 15: 100186.
GHUSN W, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight
or obesity. JAMA Network Open, 2022; 5(9): e2231982.
HE L, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Frontiers in Pharmacology, 2024; 15: 1416985.
JENSEN SBK, et al. Healthy weight loss maintenance with exercise, glucagon-like peptide-1 receptor agonist, or both combined. EClinicalMedicine, 2024; 69: 102475.
JOHNSON BVB, et al. Diet quality and nutrient distribution while using glucagon-like peptide-1 receptor agonist. Obesity Pillars, 2025; 16: 100195.
JOHNSON SM, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition, 2025; 12: 1566498.
MARQUES AS, et al. Mobilização precoce em pacientes adultos na UTI: uma revisão de literatura. Rev Iberoam Humanid Ciênc Educ., 2023; 9(8): 519-28.
MELIŠ, P et al. The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus: a pilot study. Diabetes, Obesity and Metabolism, 2025; 27: 3542-3545.
MELNYK BM, FINEOUT-OVERHOLT, E Evidence-based practice in nursing & healthcare: a guide to best practice. 4th ed. Philadelphia: Wolters Kluwer, 2019.
MENDES KDS, et al. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem, 2008; 17(4): 758-764.
PANTANETTI, P et al. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide. Frontiers in Endocrinology, 2024; 15: 1394506.
PONZO V, et al. Exploring dietary intake in adults with type 2 diabetes using GLP-1 receptor agonists. Nutrients, 2025; 17(21): 3318.
REGINA C, et al. O trabalho multiprofissional com grupo de diabéticos. Revista Brasileira de Enfermagem. 2006;59(6):812–9.
RODRIGUES SE, et al. Fatores que dificultam a adesão à terapia nutricional em indivíduos com diabetes mellitus tipo 2: uma revisão integrativa. Rev Bras Obes Nutr Emagrecimento, 2024; 18(112): 143-151.
SOUZA NP, et al. Atlas da situação alimentar e nutricional em Pernambuco. ECOASUSPE, 2021; 1: 1–83.
WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: World Health Organization, s.d. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Acesso em: 2 nov. 2025.
COLLINS L, COSTELLO RA. Glucagon-Like Peptide-1 Receptor Agonists. Treasure Island (FL): StatPearls Publishing; 2024.
YOUNG KG, et al. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Communications medicine. 2023; 3: 131.
WU T, et al. Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database. Clinical Drug Investigation, 2022; 42: 965-975.